Matthias Kloor

List of Publications by Year in descending order

119 papers	9,151 citations	53794 45 h-index	43889 91 g-index
126 all docs	126 docs citations	126 times ranked	13358 citing authors

#	Article	IF	Citations
1	Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1373-1382.	2.5	4
2	Weakly supervised annotationâ€free cancer detection and prediction of genotype in routine histopathology. Journal of Pathology, 2022, 256, 50-60.	4.5	48
3	Adenoma and colorectal cancer risks in Lynch syndrome, Lynchâ€like syndrome and familial colorectal cancer type X. International Journal of Cancer, 2022, 150, 56-66.	5.1	2
4	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology, 2022, 162, 907-919.e10.	1.3	27
5	Vaccines for immunoprevention of DNA mismatch repair deficient cancers. , 2022, 10, e004416.		21
6	The â€œunnaturalâ€•history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. International Journal of Cancer, 2021, 148, 800-811.	5.1	55
7	Does Side Really Matter? Survival Analysis among Patients with Right- Versus Left-Sided Colon Cancer: A Propensity Score-Adjusted Analysis. Annals of Surgical Oncology, 2021, 28, 2768-2778.	1.5	11
8	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	7.7	52
9	Value of upper <scp>gastrointestinal</scp> endoscopy for gastric cancer surveillance in patients with Lynch syndrome. International Journal of Cancer, 2021, 148, 106-114.	5.1	28
10	Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort. International Journal of Colorectal Disease, 2021, 36, 177-185.	2.2	1
11	Deep learning detects genetic alterations in cancer histology generated by adversarial networks. Journal of Pathology, 2021, 254, 70-79.	4.5	31
12	NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes. IScience, 2021, 24, 102389.	4.1	22
13	Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure. PLoS Computational Biology, 2021, 17, e1008970.	3.2	11
14	Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers. Frontiers in Oncology, 2021, 11, 669774.	2.8	11
15	Differential Glycosite Profilingâ€”A Versatile Method to Compare Membrane Glycoproteomes. Molecules, 2021, 26, 3564.	3.8	0
16	Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance. Journal of Clinical Medicine, 2021, 10, 2458.	2.4	3
17	A computational model for investigating the evolution of colonic crypts during Lynch syndrome carcinogenesis. Computational and Systems Oncology, 2021, 1, e1020.	1.5	0
18	Early detection of duodenal cancer by upper <scp>gastrointestinal</scp>â€endoscopy in Lynch syndrome. International Journal of Cancer, 2021, 149, 2052-2062.	5.1	4

#	Article	IF	Citations
19	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers, 2021, 13, 3817.	3.7	15
20	Treatment resistance analysis reveals GLUTâ€1â€mediated glucose uptake as a major target of synthetic rocaglates in cancer cells. Cancer Medicine, 2021, 10, 6807-6822.	2.8	2
21	The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. Experimental and Molecular Pathology, 2021, 122, 104668.	2.1	8
22	Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology, 2021, 161, 1288-1302.e13.	1.3	56
23	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	7.3	42
24	Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a populationâ€based study. Molecular Oncology, 2020, 14, 363-372.	4.6	23
25	Association of BMI and major molecular pathological markers of colorectal cancer in men and women. American Journal of Clinical Nutrition, 2020, 111, 562-569.	4.7	15
26	(Phospho)proteomic Profiling of Microsatellite Unstable CRC Cells Reveals Alterations in Nuclear Signaling and Cholesterol Metabolism Caused by Frameshift Mutation of NMD Regulator UPF3A. International Journal of Molecular Sciences, 2020, 21, 5234.	4.1	6
27	The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nature Communications, 2020, 11, 4740.	12.8	78
28	Ageâ€dependent performance of <scp>BRAF</scp> mutation testing in Lynch syndrome diagnostics. International Journal of Cancer, 2020, 147, 2801-2810.	5.1	17
29	Identification of MLH2/hPMS1 dominant mutations that prevent DNA mismatch repair function. Communications Biology, 2020, 3, 751.	4.4	5
30	The majority of Î²-catenin mutations in colorectal cancer is homozygous. BMC Cancer, 2020, 20, 1038.	2.6	25
31	Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes: A Population-Based Case-Control Study. American Journal of Gastroenterology, 2020, 115, 2007-2016.	0.4	18
32	A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial. Clinical Cancer Research, 2020, 26, 4503-4510.	7.0	81
33	Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review. Journal of Clinical Medicine, 2020, 9, 1741.	2.4	22
34	Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways. International Journal of Cancer, 2020, 147, 1018-1026.	5.1	12
35	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	1.3	60
36	Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways. British Journal of Cancer, 2020, 122, 1604-1610.	6.4	52

#	Article	IF	Citations
37	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. BMC Cancer, 2020, 20, 460.	2.6	32
38	Genetic Variants in the Regulatory T cellâ€“Related Pathway and Colorectal Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2719-2728.	2.5	1
39	The Association Between Mutations in BRAF and Colorectal Cancerâ€“Specific Survival Depends on Microsatellite Status and Tumor Stage. Clinical Gastroenterology and Hepatology, 2019, 17, 455-462.e6.	4.4	62
40	External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. BMC Cancer, 2019, 19, 681.	2.6	18
41	A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival. Clinical Epigenetics, 2019, 11, 109.	4.1	4
42	High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer. British Journal of Cancer, 2019, 121, 395-404.	6.4	20
43	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	1.5	27
44	Low frequency of mismatch repair deficiency in gallbladder cancer. Diagnostic Pathology, 2019, 14, 36.	2.0	19
45	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
46	E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer . Cancer Management and Research, 2019, Volume 11, 1795-1803.	1.9	18
47	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care, 2019, 14, 53-59.	1.4	13
48	Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. Journal of the National Cancer Institute, 2019, 111, 475-483.	6.3	34
49	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. British Journal of Cancer, 2019, 120, 109-114.	6.4	71
50	Prognostic significance of microsatelliteâ€instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. International Journal of Cancer, 2019, 144, 1697-1703.	5.1	51
51	Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 402-410.e2.	4.4	44
52	Resistance of the stableâ€”towards more precise prediction of response to immune checkpoint blockade in microsatellite-unstable cancer patients. Annals of Translational Medicine, 2019, 7, 603-603.	1.7	0
53	Complex pattern of immune evasion in MSI colorectal cancer. OncoImmunology, 2018, 7, e1445453.	4.6	90
54	Three molecular pathways model colorectal carcinogenesis in <scp>L</scp>ynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	5.1	129

#	Article	IF	Citations
55	High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. OncoImmunology, 2018, 7, e1390640.	4.6	48
56	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology, 2018, 155, 1400-1409.e2.	1.3	112
57	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	4.6	60
58	The Immune Biology of Microsatellite Unstable Cancer. , 2018, , 367-384.		4
59	Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas.. Journal of Clinical Oncology, 2018, 36, 1555-1555.	1.6	3
60	Hematological Malignancies in Adults With a Family Predisposition. Deutsches Ärzteblatt International, 2018, 115, 848-854.	0.9	9
61	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 2017, 30, 610-619.	5.5	131
62	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. OncoImmunology, 2017, 6, e1171447.	4.6	64
63	The association between microsatellite instability and lymph node count in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 57-64.	2.8	12
64	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. Journal of Pathology, 2017, 243, 242-254.	4.5	69
65	Analyzing epigenetic control of galectin expression indicates silencing of galectinâ€12 by promoter methylation in colorectal cancer. IUBMB Life, 2017, 69, 962-970.	3.4	8
66	Associations of red and processed meat intake with major molecular pathological features of colorectal cancer. European Journal of Epidemiology, 2017, 32, 409-418.	5.7	34
67	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Journal of Physical Education and Sports Management, 2017, 3, a001974.	1.2	54
68	A phase 1/2a study to test the safety and immunogenicity of a p16^{INK4a} peptide vaccine in patients with advanced human papillomavirusâ€associated cancers. Cancer, 2016, 122, 1425-1433.	4.1	33
69	Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunology, 2016, 5, e1075692.	4.6	28
70	The Immune Biology of Microsatellite-Unstable Cancer. Trends in Cancer, 2016, 2, 121-133.	7.4	193
71	No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. British Journal of Cancer, 2016, 115, 1359-1366.	6.4	43
72	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes and Cancer, 2016, 55, 268-277.	2.8	28

#	Article	IF	Citations
73	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	2.8	34
74	Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 313-319.	2.8	60
75	CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. Familial Cancer, 2016, 15, 579-586.	1.9	75
76	Overexpression of <scp>SIX1</scp> is an independent prognostic marker in stage <scp>I</scp>â€“<scp>III</scp> colorectal cancer. International Journal of Cancer, 2015, 137, 2104-2113.	5.1	31
77	Coding Microsatellite Frameshift Mutations Accumulate in Atherosclerotic Carotid Artery Lesions: Evaluation of 26 Cases and Literature Review. Molecular Medicine, 2015, 21, 479-486.	4.4	4
78	Detection of coding microsatellite frameshift mutations in DNA mismatch repairâ€deficient mouse intestinal tumors. Molecular Carcinogenesis, 2015, 54, 1376-1386.	2.7	33
79	Doseâ€dependent effect of 2â€deoxyâ€Dâ€glucose on glycoprotein mannosylation in cancer cells. IUBMB Life, 2015, 67, 218-226.	3.4	16
80	Statin Use and Survival After Colorectal Cancer: The Importance of Comprehensive Confounder Adjustment. Journal of the National Cancer Institute, 2015, 107, djv045.	6.3	91
81	Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunology, Immunotherapy, 2015, 64, 357-366.	4.2	41
82	Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome â€“ Molecular Alterations and Association with Clinical Parameters. PLoS ONE, 2015, 10, e0121980.	2.5	57
83	Potential of fecal microbiota for earlyâ€stage detection of colorectal cancer. Molecular Systems Biology, 2014, 10, 766.	7.2	991
84	Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. Clinical Cancer Research, 2014, 20, 6593-6604.	7.0	145
85	Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3. Carcinogenesis, 2014, 35, 315-323.	2.8	31
86	Clinical significance of microsatellite instability in colorectal cancer. Langenbeck's Archives of Surgery, 2014, 399, 23-31.	1.9	52
87	Colorectal cancer. Lancet, The, 2014, 383, 1490-1502.	13.7	2,455
88	No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16INK4a status. Human Pathology, 2014, 45, 2347-2354.	2.0	17
89	BRAF V600Eâ€specific immunohistochemistry for the exclusion of Lynch syndrome in MSIâ€H colorectal cancer. International Journal of Cancer, 2013, 133, 1624-1630.	5.1	93
90	T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 27-37.	4.2	46

#	Article	IF	Citations
91	Towards a vaccine to prevent cancer in Lynch syndrome patients. Familial Cancer, 2013, 12, 307-312.	1.9	54
92	The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Modern Pathology, 2012, 25, 911-916.	5.5	49
93	Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncology, The, 2012, 13, 598-606.	10.7	147
94	Lynch syndrome: clinical, pathological, and genetic insights. Langenbeck's Archives of Surgery, 2012, 397, 513-525.	1.9	16
95	Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Familial Cancer, 2011, 10, 557-565.	1.9	45
96	Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. Journal of Medical Genetics, 2011, 48, 513-519.	3.2	68
97	Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Modern Pathology, 2011, 24, 564-570.	5.5	51
98	Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro. Clinical Cancer Research, 2011, 17, 7654-7663.	7.0	132
99	Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome. Journal of Clinical Oncology, 2011, 29, 223-227.	1.6	46
100	Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Familial Cancer, 2010, 9, 173-179.	1.9	47
101	Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. International Journal of Cancer, 2010, 127, 889-898.	5.1	46
102	Immune evasion of microsatellite unstable colorectal cancers. International Journal of Cancer, 2010, 127, 1001-1010.	5.1	120
103	Efficacy of Annual Colonoscopic Surveillance in Individuals With Hereditary Nonpolyposis Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2010, 8, 174-182.	4.4	160
104	High Frequency of LMAN1 Abnormalities in Colorectal Tumors with Microsatellite Instability. Cancer Research, 2009, 69, 292-299.	0.9	29
105	Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers. Gastroenterology, 2008, 134, 988-997.	1.3	319
106	Beta2â€microglobulin mutations in microsatellite unstable colorectal tumors. International Journal of Cancer, 2007, 121, 454-458.	5.1	100
107	The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes and Cancer, 2007, 46, 1080-1089.	2.8	79
108	Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomarkers, 2006, 2, 69-86.	1.7	71

#	Article	IF	Citations
109	Tetranucleotide repeats in coding regions: no evidence for involvement in EMAST carcinogenesis. Journal of Molecular Medicine, 2006, 84, 329-333.	3.9	11
110	Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2006, 118, 115-122.	5.1	98
111	Genotype-Phenotype Comparison of German MLH1 and MSH2 Mutation Carriers Clinically Affected With Lynch Syndrome: A Report by the German HNPCC Consortium. Journal of Clinical Oncology, 2006, 24, 4285-4292.	1.6	149
112	Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene, 2005, 24, 2525-2535.	5.9	76
113	Spectrum and frequencies of mutations inMSH2 andMLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2005, 116, 692-702.	5.1	113
114	Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers. Cancer Research, 2005, 65, 6418-6424.	0.9	139
115	Molecular testing for microsatellite instability and its value in tumor characterization. Expert Review of Molecular Diagnostics, 2005, 5, 599-611.	3.1	11
116	Microsatellite Analysis of Hereditary Nonpolyposis Colorectal Cancer-Associated Colorectal Adenomas by Laser-Assisted Microdissection. Journal of Molecular Diagnostics, 2005, 7, 160-170.	2.8	49
117	T25 Repeat in the 3â€² Untranslated Region of the CASP2 Gene: A Sensitive and Specific Marker for Microsatellite Instability in Colorectal Cancer. Cancer Research, 2005, 65, 8072-8078.	0.9	125
118	A large MSH2 Alu insertion mutation causes HNPCC in a German kindred. Human Genetics, 2004, 115, 432-438.	3.8	32
119	Identification and characterization of UEV3, a human cDNA with similarities to inactive E2 ubiquitin-conjugating enzymes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1579, 219-224.	2.4	9